The main value of the COME HOME model for oncology practices is that it can help reduce hospitalization rates, leading to better quality of life for patients and clinicians, according to Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.
The main value of the COME HOME model for oncology practices is that it can help reduce hospitalization rates, leading to better quality of life for patients and clinicians, according to Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants.
Transcript (slightly modified)
Are the oncology practices using COME HOME better equipped to fulfill requirements for the Quality Payment Program?
I believe that that is the main value of COME HOME. The processes that we’ve put in place with the triage pathways, where we give nurses the power of the schedule and a decision support tool to be able to make sure that they’re making the decisions that their physicians would want made, getting patients into the office for same-day visits, that’s what worked in COME HOME to cut down hospitalization rates.
Patients do better when they’re not in the hospital. Every time a patient goes into the hospital, they come out just a little less quality of life than they went in. They’re just not as strong or they got a bad infection or something else happened. So by keeping patients out of the hospital, we keep them healthier, which is the main goal, but we also save that money. That’s the low-hanging fruit.
The processes we created with COME HOME have allowed us to do multiple same-day visits and in my practice, we’ve cut our hospital admissions by over half, and that’s significant. It’s also significant not only for patient quality of life but for physician quality of life. If I don’t have so many people to round on in the hospital before I go to the office to do the day’s work, I can manage them much more easily.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bias Reduction, Better Access Key to COVID-19 Equity Gains
April 14th 2025Interventions that target enhancing health care equity among communities disproportionately affected by the COVID-19 pandemic can be improved by including comprehensive needs assessments at the patient, provider, and health system levels.
Read More